Warren Buffett is sitting on $325 billion in cash – his largest hoard ever.
Not because he wants to – but because he can’t find value in the usual places.
Now, as US government spending spirals out of control, Buffett knows he’s losing billions of dollars to inflation.
That’s why I predict Buffett’s next investment will catch millions of people off guard.
It’s not another bank… railroad company… or more shares of Apple.
It’s a gold company. How do I know?
Because the math doesn’t lie:
You can buy the average gold developer for $30 and get back $13 a year —
That’s a 43% ROI annually.
Over 10 years, that’s $130 on a $30 investment.
Tell me where else Buffett can get that.
But there’s one specific miner Buffett likes best:
- It’s the best-managed major gold miner in the industry…
- Has massive cash flow…
- Is trading at a deep discount to fair value…
- Positioned at the heart of Trump’s new mining push…
Don’t wait for Buffett to reveal his position in his 13F filing on February 17th…
Right now, you have the chance to front-run the greatest investor of all time. Go here and I’ll give you the name and ticker – along with details on my top four small miners.
To your wealth,
Garrett Goggin, CFA, CMT
Chief Analyst & Founder, Golden Portfolio
P.S. A lot of investors write in to tell me how much they’ve made in Bitcoin. My reply? Good for you. First off, gold investing is cyclical. You really only want to own gold at one specific time in the cycle. That time is now. Second, the world’s governments are not buying Bitcoin. They’re betting on gold. All of them. Bitcoin (does anyone really know for sure the US government didn’t create it?) will be a good bet… until it isn’t. It may end up doing great. Or it may be eclipsed by any number of tech developments.
Meanwhile, gold will continue to do what it’s done for almost 6,000 years of recorded human history: Protect wealth through chaos. Go here if you want the name and ticker of Buffett’s likely gold play… and details on my top four miners
Investors Have WING. Do They Need a Prayer?
Reported by Thomas Hughes. Article Posted: 2/20/2026.
Key Points
- Wingstop is on track to accelerate growth in 2026 and sustain a robust capital return.
- High debt is offset by cash flow, coverage, and growth.
- Analysts are raising targets, leading this market toward record highs.
- Special Report: [Sponsorship-Ad-6-Format3]
Wingstop (NASDAQ: WING) investors' prayers were answered with the Q4 2025 earnings release and 2026 guidance. Not only were the Q4 comps better than expected, but margin strength stood out and the guidance affirmed an outlook for acceleration.
The company now forecasts low-single-digit domestic comps and 15% global store-count growth. Combined with last year's roughly 20% increase in store count, that suggests consensus estimates could be too conservative.
Silver $309? (Ad)
Silver: 20% + 68%
Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now.
The likely outcome is that the price rebound catalyzed by the news is only the beginning of a larger move that could take the stock back toward record levels, as an outperformance / bullish-revision cycle appears to be in place. The analyst activity leading up to the release was constructive, including upgrades and price-target revisions up to the day before the report. Analyst coverage increased even while the share price had been declining.
The consensus Moderate Buy rating is firming and price targets are tightening around the consensus, which implies more than 20% upside from the stock's critical support level. A move to the consensus would be meaningful — it would mark a six-month high and put the market on track to retest all-time highs later in the year.
Wingstop Leans Into Store Count Growth
Wingstop experienced weak domestic comps in Q4 and through 2025, but offset that performance with aggressive store-count expansion. Results showed an 8.6% year-over-year revenue gain and a 9.3% increase in systemwide sales, despite a 5.8% decline in domestic comps.
Store count rose by 124 locations in the quarter and was up about 20% year over year. Management expects openings to remain robust this year, which should improve operational leverage as consumer habits normalize. Digital sales are another bright spot — up nearly 75% — highlighting the effectiveness of the Smart Kitchen initiative. Smart Kitchen is an AI-driven tool that organizes and prioritizes off-premise orders, helping reduce ticket times by as much as 50%.
Margin strength was an important catalyst for the stock's move. Investors had braced for margin pressure but were relieved by the results. While adjusted net income was roughly flat year over year, adjusted EBITDA expanded by about 950 basis points and both metrics exceeded forecasts. More importantly, adjusted EPS of $1 topped expectations by a wide margin, and guidance for the coming year looks solid.
Aggressive Capital Return Underpins Wingstop's Stock-Price Outlook
Wingstop uses debt to fund expansion and is considered moderately to highly leveraged. Still, its margin improvement and healthy cash flow support both coverage and shareholder returns. The dividend yield is modest (just under 0.5% as of mid-February) but the payout ratio is below 30%, and management expects double-digit dividend growth in the years ahead.
The buyback program is the more impactful capital-return tool. The company reduced share count by roughly 4.9% in Q4 and about 4.4% for the fiscal year. The only notable balance-sheet wrinkle is negative shareholders' equity, but the company's cash flow and growth profile help offset that. If buybacks continue at pace, the reported equity deficit may persist as the share count falls.
Institutional activity shows a persistent appetite for Wingstop's growth, cash-flow, and capital-return story. MarketBeat data indicate a bullish institutional balance for six consecutive quarters, including Q1 2026. Institutional buying ramped to historical highs in 2025 as the stock fell and is on track to set another record in Q1 2026, which has supported recent price action.
Institutions provide a solid support base by controlling a very large portion of outstanding shares and create a robust tailwind when they buy. The biggest near-term risk is relatively high short interest (around 14%), which can cap gains; however, short covering could also contribute to upside over time.
Wingstop Confirms Bottom With February Price Action
Wingstop's share price fell to long-term lows ahead of the release and rebounded sharply afterward. The action confirms support at a critical level, aligns with prior lows, and signals a strong potential for a sustained recovery. The move pushed the market above a cluster of EMAs, which now act as key support. If that support holds, WING shares are likely to move into the $320–$360 range, consistent with analyst estimates, ahead of the Q1 2026 earnings report scheduled for mid-spring.
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
Written by Chris Markoch. Published: 2/19/2026.
Key Points
- CRISPR Therapeutics’ Q4 reaction reflects longer-term optimism despite weak reported revenue tied to launch economics.
- CASGEVY adoption is a key narrative driver, but profitability hinges on timing, revenue-sharing mechanics, and pipeline progress.
- With substantial cash on hand, the near-term question is technical/entry risk, while the long-term question is execution.
- Special Report: [Sponsorship-Ad-6-Format3]
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene-editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem counterintuitive.
The company posted a larger net loss than forecast, and revenue fell far short of expectations.
Silver $309? (Ad)
Silver: 20% + 68%
Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now.
CRISPR is a long-term story still in the early innings. The company has moved beyond proof of concept, but investors will need patience; meaningful payoff from a mature growth phase is likely a year or two away.
Putting the Earnings Report Into Context
In December 2023, CRISPR received U.S. Food & Drug Administration (FDA) approval for CASGEVY, its flagship gene therapy for sickle cell disease and beta thalassemia. CASGEVY was the first FDA-approved therapy using CRISPR/Cas9 gene-editing technology.
CRSP stock, however, is down roughly 19% since that announcement. Part of the decline reflects growth expectations that were already priced in, but the structure of CRISPR's partnership with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) also plays a role.
The Vertex partnership was critical to getting CASGEVY to market, but revenue recognition is tied to a cost-recovery arrangement: CRISPR recognizes revenue only after Vertex recoups certain launch and manufacturing costs. So while CASGEVY generated $54 million in the most recent quarter, CRISPR reported quarterly revenue of just $0.86 million.
That frames the investment thesis for CRSP stock. On one hand, CASGEVY adoption is increasing; on the other, the company is reporting larger operating losses as it advances additional pipeline candidates. The key metric may be CRISPR's cash and investments balance of about $1.9 billion, which should provide a runway of roughly three to four years.
The Pipeline Holds the Key
Even if CASGEVY adoption accelerates, there are structural challenges to near-term profitability. These are one-time, high-cost treatments that often require payment plans stretching out revenue recognition.
That's why, as with most biotech stocks, CRISPR's pipeline matters. One of the more promising candidates is CTX611, a therapy targeting Factor XI to prevent pathological blood clots while preserving normal clotting for minor injuries.
CRISPR is currently testing CTX611 (SRSD107) in a Phase 2 trial for total knee arthroplasty (TKA), where blood clots are a common post-operative complication.
Early human data show the treatment has been well tolerated and produces strong, durable effects, with the potential for dosing as infrequently as every six weeks using the company's siRNA platform, which also enables designed reversibility.
If larger trials confirm a lower bleeding risk plus convenient, infrequent dosing, CTX611 could access a roughly $20‑billion global anticoagulation market and become a meaningful growth driver for the company.
One Thing to Check Before Getting Involved With CRSP Stock
Analyst sentiment supports a "wait-and-see" view on CRISPR Therapeutics. The consensus rating is a Hold, including two sell ratings. That mix includes a recent Underweight from Morgan Stanley, which assigned a $33 price target — roughly in the range of the stock's 52-week low.
While the broader technical picture doesn't necessarily point to such a steep decline (a fall to that level would be about a 37% drop), it's notable that, as of this writing, CRSP was trading at the 200-day moving average. That level has acted as support since November; a confirmed break below it could bring additional sellers into the market.
CRSP Stock Is One to Own, Not Trade
Long-term CRSP shareholders have seen substantial returns. Since the company's IPO in 2016, investors have received a total return of more than 277%. That performance was bolstered by a speculative surge in 2020–2021, which likely prompted some profit-taking afterward.
The takeaway: CRISPR Therapeutics is delivering on aspects of its pipeline, but progress is not as rapid as some investors expected. CRSP may not suit short-term traders seeking quick, sharp moves. It could, however, be an attractive holding for investors with a longer time horizon who can wait for the potential for significant gains by the end of the decade.
This email is a sponsored message provided by Golden Portfolio, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you need assistance with your newsletter, please contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl. #620, Sioux Falls, South Dakota 57103. United States of America..
No comments:
Post a Comment